Bone marrow transplantation versus chemotherapy in non-hodgkin's lymphoma

John F. Seymour, Steve Flecknoe-Brown, Klaus Mross, Harry B. Burke, Stephen D. Nimer, Andrew Zelenetz, Carol Portlock, Waltraud Finckh, Adele K. Fielding, Rachel M. Pearce, Anthony H. Goldstone, Murray R. Selwyn, Leo F. Verdonck, Wim L.j. Van Putten, Anton Hagenbeek, Alexander M. Walker

Research output: Contribution to journalLetterpeer-review

1 Scopus citations


To the Editor: In their study of the efficacy of high-dose chemotherapy and autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma who respond slowly to chemotherapy, Verdonck et al. (April 20 issue)1 used response criteria that may have influenced the outcome. A variety of criteria have been proposed to assess response in patients with lymphoma, but the most widely accepted are those ratified at the Cotswolds meeting,2 which define a partial remission as “a decrease by at least 50 percent in the sum of the products of the largest perpendicular diameters of all measurable lesions.” In contrast, Verdonck et.

Original languageEnglish
Pages (from-to)727-730
Number of pages4
JournalNew England Journal of Medicine
Issue number11
StatePublished - 14 Sep 1995
Externally publishedYes


Dive into the research topics of 'Bone marrow transplantation versus chemotherapy in non-hodgkin's lymphoma'. Together they form a unique fingerprint.

Cite this